Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy

 
• By Lucie Ellis-Taitt

Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.

Handshake of businessmen
• Source: Shutterstock

Rising Leaders Home

Prior to joining Synaffix B.V., Anthony DeBoer was associate director of business development at Allozyne, a Seattle-based biotech, where...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rising Leaders

More from Leadership